{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:27:31Z","timestamp":1787120851129,"version":"build-2736575974"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pembrolizumab, an immune checkpoint inhibitor (ICI) targeting programmed cell death protein 1 (PD-1), has demonstrated significant clinical value in the treatment of human epidermal growth factor receptor 2 (HER2)-negative advanced gastric cancer (GC) and gastroesophageal junction cancer (GEJC). However, due to the relatively short duration of existing studies, inconsistent survival benefits among patients, and the lack of a standardized risk assessment system, its efficacy and safety still remain controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>By systematically querying the following English-language databases, including PubMed, Embase, Web of Science, Scopus, Ovid, Cochrane Library, and CINAHL, along with the clinical trial registry ClinicalTrials.gov, studies reporting clinical efficacy and safety outcomes of pembrolizumab in patients with HER2-negative advanced GC or GEJC were identified. A meta analysis was subsequently conducted to pool objective response rate (ORR), duration of response (DoR), overall survival (OS), progression free survival (PFS), 12\/24-month overall survival rate (OS-12\/24), 12\/24-month progression-free survival rate (PFS-12\/24), as well as treatment related adverse events (TRAEs) and immune related adverse events (irAEs). Comprehensive subgroup analyses were further performed based on PD-L1 combined positive score (CPS), age, region, chemo backbone, and median follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nine studies encompassing 3406 patients with HER2-negative advanced GC or GEJC were included. In randomized controlled trials (RCTs), pembrolizumab plus chemotherapy significantly improved ORR (OR 1.57, 95%CI:1.35-1.81) and OS (HR 0.82, 95%CI:0.75-0.89) compared with chemotherapy alone. Pooled median PFS from RCTs in the pembrolizumab arm was 6.77 months (95%CI:6.19-7.36) and from single-arm studies was 6.53 months (95%CI:4.59-9.31). Combination chemotherapy regimens showed numerically longer median OS (RCT combination subgroup median OS (mOS) 12.74 months\n                      <jats:italic>vs<\/jats:italic>\n                      monotherapy subgroup 10.60 months; single-arm combination cohort mOS 16.96 months). The most common TRAEs was decreased neutrophil count with an incidence of 24.9%, which was also the most common grade 3 or higher event. The most common irAEs was hypothyroidism (pooled incidence 21.4% in RCTs). Overall toxicity was manageable and safety outcomes were consistent across studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pembrolizumab in conjunction with chemotherapy confers substantial clinical advantage in the management of HER2-negative advanced GC or GEJC, as evidenced by improvements in ORR, OS, and PFS. In contrast, the therapeutic efficacy of pembrolizumab monotherapy appears constrained. Vigilant surveillance for heightened hematologic and gastrointestinal toxicities is warranted within routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD420261298020.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1862751","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:46:26Z","timestamp":1787118386000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy and safety of pembrolizumab in the treatment of HER2-negative advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis of emerging clinical data"],"prefix":"10.3389","volume":"17","author":[{"given":"Ying","family":"Yang","sequence":"first","affiliation":[{"name":"Oncology Department, Guang\u2019anmen Hospital of China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Jiang","sequence":"additional","affiliation":[{"name":"Oncology Department, Guang\u2019anmen Hospital of China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Oncology Department, Guang\u2019anmen Hospital of China Academy of Chinese Medical Sciences","place":["Beijing, China"]},{"name":"Graduate School, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[{"name":"Oncology Department, Guang\u2019anmen Hospital of China Academy of Chinese Medical Sciences","place":["Beijing, China"]},{"name":"Graduate School, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daorui","family":"Li","sequence":"additional","affiliation":[{"name":"Oncology Department, Guang\u2019anmen Hospital of China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1312","article-title":"The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer","volume":"13","author":"Han","year":"2023","journal-title":"Clin Transl Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2018.883","article-title":"Targeted literature review of the global burden of gastric cancer","volume":"12","author":"Casamayor","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2857","article-title":"Helicobacter pylori: gastric cancer and beyond","volume":"10","author":"Polk","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00052-2","article-title":"Gastric cancer","volume":"405","author":"Sundar","year":"2025","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.3012781","article-title":"The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity","volume":"232","author":"Akiyama","year":"1986","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157285","article-title":"Fighting HER2 in gastric cancer: Current approaches and future landscapes","volume":"26","author":"Ratti","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12193","article-title":"The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021","volume":"41","author":"Wang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mdy502","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS","volume":"30","author":"Muro","year":"2019","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1231","article-title":"Gemcitabine synergizes with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients","volume":"24","author":"Tall\u00f3n de Lara","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: The ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2482363","article-title":"Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer","volume":"21","author":"Sternschuss","year":"2025","journal-title":"Future Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03566-1","article-title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial","volume":"31","author":"Eskander","year":"2025","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2508959","article-title":"Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115395","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study","volume":"221","author":"Tahara","year":"2025","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12876-025-03754-w","article-title":"Efficacy and safety of pembrolizumab in advanced gastric and gastroesophageal junction cancer: a systematic review and meta-analysis","volume":"25","author":"Ji","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s12029-025-01347-0","article-title":"Efficacy and safety of different treatment regimens for previously untreated patients with HER2-positive advanced gastric cancer: a meta-analysis of randomized controlled trials","volume":"56","author":"He","year":"2025","journal-title":"J Gastrointest Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1566939","article-title":"The efficacy and safety of PD-1\/PD-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresectable, locally advanced, HER2-negative gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials","volume":"16","author":"Pu","year":"2025","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.Ed000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jclinepi.2021.08.022","article-title":"Cochrane's risk of bias tool for non-randomized studies (ROBINS-I) is frequently misapplied: a methodological systematic review","volume":"140","author":"Igelstr\u00f6m","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"B31","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (Updated August 2024)","author":"Higgins","year":"2024"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00748","article-title":"Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced metastatic gastroesophageal adenocarcinoma: the phase III, randomized LEAP-015 study","volume":"43","author":"Shitara","year":"2025","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-018-00909-5","article-title":"Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study","volume":"22","author":"Bang","year":"2019","journal-title":"Gastric Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ejca.2020.02.002","article-title":"Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric\/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study","volume":"129","author":"Kawazoe","year":"2020","journal-title":"Eur J Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15462","article-title":"Phase IIb study of pembrolizumab combined with S-1 +\u2009oxaliplatin or S-1 +\u2009cisplatin as first-line chemotherapy for gastric cancer","volume":"113","author":"Yamaguchi","year":"2022","journal-title":"Cancer Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102985","article-title":"Ramucirumab in combination with pembrolizumab in treatment-na\u00efve advanced gastric or GEJ adenocarcinoma: safety and antitumor activity from the phase 1a\/b JVDF trial","volume":"12","author":"Chau","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/cells11193033","article-title":"Immunogenic cell death: an emerging target in gastrointestinal cancers","volume":"11","author":"Chiaravalli","year":"2022","journal-title":"Cells"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0857","article-title":"Early immune remodeling steers clinical response to first-line chemoimmunotherapy in advanced gastric cancer","volume":"14","author":"An","year":"2024","journal-title":"Cancer Discov"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71065","article-title":"Current advances and future directions for sensitizing gastric cancer to immune checkpoint inhibitors","volume":"14","author":"Li","year":"2025","journal-title":"Cancer Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s10238-025-01610-5","article-title":"Evaluating comparative effectiveness of pembrolizumab-based therapy versus chemotherapy in treatment of gastric carcinoma: a systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Mansoor","year":"2025","journal-title":"Clin Exp Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000540071","article-title":"Meta-analysis of the efficacy and safety of pembrolizumab in the treatment of advanced gastric cancer and gastroesophageal junction cancer","volume":"70","author":"Yang","year":"2025","journal-title":"Chemotherapy"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2238896","article-title":"Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis","volume":"23","author":"Noori","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.4_suppl.464","article-title":"Pembrolizumab or placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma: an updated analysis of KEYNOTE-859 for patients enrolled in Asia","volume":"43","author":"Yen","year":"2025","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"52","DOI":"10.21037\/cco-24-48","article-title":"PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma\u2014a commentary on KEYNOTE-811","volume":"13","author":"Yu","year":"2024","journal-title":"Chin Clin Oncol"},{"key":"B48","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 1.2026","year":"2026"},{"key":"B49","volume-title":"Chinese Society of Clinical Oncology (Csco) Guidelines for the Diagnosis and Treatment of Gastric Cancer (2025)","year":"2025"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00314","article-title":"Tumor mutational burden determined by panel sequencing predicts survival after immunotherapy in patients with advanced gastric cancer","volume":"10","author":"Kim","year":"2020","journal-title":"Front Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-025-01618-6","article-title":"Predictive value of EBV-positivity in patients with gastric cancer treated with first-line nivolumab plus chemotherapy","volume":"28","author":"Kim","year":"2025","journal-title":"Gastric Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4043","article-title":"Immune checkpoint inhibition in EBV-associated gastric cancer: A multi-center international retrospective analysis","volume":"43","author":"Cowzer","year":"2025","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s40001-023-01365-3","article-title":"Mechanisms and biomarkers of immune-related adverse events in gastric cancer","volume":"28","author":"Ding","year":"2023","journal-title":"Eur J Med Res"},{"key":"B54","article-title":"Safety profile of checkpoint inhibitors across ESCC and gastric\/GEJ tumors","author":"Ilson","year":"2025","journal-title":"Target Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1862751\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:46:28Z","timestamp":1787118388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1862751\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2026.1862751"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1862751","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1862751"}}